跳至主要内容
临床试验/NCT02777892
NCT02777892已完成不适用

Pulmonic SAPIEN S3™ THV Registry A Multi-center, Observational Registry With Retrospective Enrollment of Patients That Underwent Transcatheter Pulmonic Valve Implantation and a Retrospective or Prospective Follow-up

Institut für Pharmakologie und Präventive Medizin4 个研究点 分布在 3 个国家目标入组 50 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
4
主要终点
changes in right ventricular and pulmonary artery pressure

研究概览

简要总结

Multi-center, Observational Registry with Retrospective Enrollment and Prospective Follow-up.

The aim of the registry is to document the feasibility and safety of implanting an Edwards SAPIEN S3 transcatheter heart valve in the pulmonic position

详细描述

A malfunction or dysplasia of the pulmonary valve or the right ventricular outflow tract (RVOT) is one of the major components of the cardiac physiology in many congenital heart defects. Surgical correction of complex heart defects often includes some form of surgical repair or replacement of the native RVOT by biological valves such as homograft, bioprosthesis or Xenografts (i.e., Contegra conduits). Typical examples are tetralogy of Fallot (TOF) or double outlet right ventricle (DORV), pulmonary stenosis (PS), pulmonary atresia (PA), truncus arteriosus (TA), transposition of the great arteries (TGA) with PS (Rastelli's operation), absent pulmonary valve syndrome (Miller-Lev-Paul), Ross surgery for aortic valve disease and others. The repaired or replaced pulmonary valve however often becomes dysfunctional later on and many patients require surgical revisions of the RVOT with pulmonary valve replacement within 10 years of primary intervention.

TPVI provides a less invasive alternative to surgery in patients with right ventricular-to-pulmonary artery (RV-PA) conduit dysfunction. Early results of percutaneous pulmonary valve implantation (PPVI) showed that it is a promising procedure compared to a conventional surgical intervention. Meanwhile, pre-stenting of the RVOT before PPVI is routinely performed, enabling PPVI in various anatomies.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

changes in right ventricular and pulmonary artery pressure

时间窗: from baseline to 30 days after implantation

次要结局

  • Max. flow velocity RVOT(30 days after implantation)
  • Changes in NYHA class(from baseline to 30 days after implantation)
  • changes in degree of pulmonary regurgitation(from baseline to 30 days after implantation)
  • changes in Peak Oxygen consumption(from baseline to 24 months after implantation)
  • Percentage of cases with proper device function(24 months after implantation)
  • Incidence of structural valve Deterioration including stent fracture(24 months after implantation)
  • length of hospitalization(30 days after implantation)

研究者

发起方
Institut für Pharmakologie und Präventive Medizin
申办方类型
Network
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验